Effect of age on drug metabolism in women with breast cancer

Bibliography

• LFHutchins, JMUnger, JJCrowley, et al. Underrepresentation of patients 65 years of age or older in cancer- treatment trials. N Engl J Med 1999;341:2061-7
   PubMed Web of Science ®Google Scholar
• SMLichtman, DRBudman. Adjuvant therapy for node-negative breast cancer. N Engl J Med 1989;321:469-73; letter
   PubMed Web of Science ®Google Scholar
• KSScher, AHurria. Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol 2012;30:2036-8
   PubMed Web of Science ®Google Scholar
• RWCarlson, SMoench, AHurria, et al. NCCN Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw 2008;6(Suppl 4):S1-S25; quiz S26-S27
   PubMedGoogle Scholar
• AHurria, KTogawa, SGMohile, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011;29:3457-65
   PubMed Web of Science ®Google Scholar
• NAde Glas, Wvan de Water, EGEngelhardt, et al. Validity of Adjuvant! Online program in older patients with breast cancer: a population-based study. Lancet Oncol 2014;15:722-9
   PubMed Web of Science ®Google Scholar
• AHurria, SMLichtman, JGardes, et al. Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice. J Am Geriatr Soc 2007;55:1604-8
   PubMed Web of Science ®Google Scholar
• AHurria, SGupta, MZauderer, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 2005;104:1998-2005
   PubMed Web of Science ®Google Scholar
• CBouchardy, ERapiti, SBlagojevic, et al. Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol 2007;25:1858-69
   PubMed Web of Science ®Google Scholar
• SGDiab, RMElledge, GMClark. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000;92:550-6
   PubMed Web of Science ®Google Scholar
• MAapro, HWildiers. Triple-negative breast cancer in the older population. Ann Oncol 2012;23(Suppl 6):vi52-5
   PubMedGoogle Scholar
• MMKemeny, BLPeterson, ABKornblith, et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 2003;21:2268-75
   PubMed Web of Science ®Google Scholar
• RLeonard, RBallinger, DCameron, et al. Adjuvant chemotherapy in older women (ACTION) study - what did we learn from the pilot phase? Br J Cancer 2011;105:1260-6
   PubMed Web of Science ®Google Scholar
• HBMuss, SWoolf, DBerry, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005;293:1073-81
   PubMed Web of Science ®Google Scholar
• BLVan Leeuwen, KMRosenkranz, LLFeng, et al. The effect of under-treatment of breast cancer in women 80 years of age and older. Crit Rev Oncol Hematol 2011;79:315-20
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative G. RPeto, CDavies, JGodwin, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432-44
   PubMed Web of Science ®Google Scholar
• HBMuss, DABerry, CTCirrincione, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009;360:2055-65
   PubMed Web of Science ®Google Scholar
• SHGiordano, ZDuan, YFKuo, et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 2006;24:2750-6
   PubMed Web of Science ®Google Scholar
• ECDees, SO’Reilly, SNGoodman, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 2000;18:521-9
   PubMed Web of Science ®Google Scholar
• APVenook, MJEgorin, GLRosner, et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 1998;16:1811-19
   PubMed Web of Science ®Google Scholar
• APVenook, MJEgorin, GLRosner, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000;18:2780-7
   PubMed Web of Science ®Google Scholar
• APVenook, CEnders Klein, GFleming, et al. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 2003;14:1783-90
   PubMed Web of Science ®Google Scholar
• SMLichtman, HWildiers, EChatelut, et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature. J Clin Oncol 2007;25:1832-43
   PubMed Web of Science ®Google Scholar
• SMLichtman, JASkirvin, SVemulapalli. Pharmacology of antineoplastic agents in older cancer patients. Crit Rev Oncol Hematol 2003;46:101-14
   PubMed Web of Science ®Google Scholar
• SDBaker, LBGrochow. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med 1997;13:169-83
   PubMed Web of Science ®Google Scholar
• GJYuen. Altered pharmacokinetics in the elderly. Clin Geriatr Med 1990;6:257-67
   PubMedGoogle Scholar
• AINeugut, MSubar, ETWilde, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 2011;29:2534-42
   PubMed Web of Science ®Google Scholar
• AHPartridge, PSWang, EPWiner, JAvorn. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21:602-6
   PubMed Web of Science ®Google Scholar
• KJRuddy, BNPitcher, LEArcher, et al. Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). Ann Oncol 2012;23:3075-81
   PubMed Web of Science ®Google Scholar
• AHPartridge, LArcher, ABKornblith, et al. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol 2010;28:2418-22
   PubMed Web of Science ®Google Scholar
• RJMaggiore, WDale, CPGross, et al. Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment. J Am Geriatr Soc 2014;62:1505-12
   PubMed Web of Science ®Google Scholar
• MPopa, KWallace, ABrunello, MExtermann. The impact of polypharmacy on toxicity from chemotherapy in elderly patients: Focus on cytochrome P-450 inhibition and protein binding effects. ASCO Meeting Abstr 2008;26:9505
   Google Scholar
• JASalazar, IPoon, MNair. Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable. Expert Opin Drug Saf 2007;6:695-704
   PubMed Web of Science ®Google Scholar
• SMLichtman, MKBoparai. Anticancer drug therapy in the older cancer patient: pharmacology and polypharmacy. Curr Treat Options Oncol 2008;9:191-203
   PubMed Web of Science ®Google Scholar
• American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60:616-31
   PubMed Web of Science ®Google Scholar
• GMMarx, GMBlake, EGalani, et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 2004;15:291-5
   PubMed Web of Science ®Google Scholar
• VLaunay-Vacher, EChatelut, SLichtman, et al. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 2007;18:1314-21
   PubMed Web of Science ®Google Scholar
• SMLichtman, HWildiers, VLaunay-Vacher, et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007;43:14-34
   PubMed Web of Science ®Google Scholar
• VLaunay-Vacher, JGligorov, CLe Tourneau, et al. Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat 2010;124:745-53
   PubMed Web of Science ®Google Scholar
• RRShah. Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II). Br J Clin Pharmacol 2004;58:452-69
   PubMed Web of Science ®Google Scholar
• RSawhney, MSehl, ANaeim. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J 2005;11:449-60
   PubMed Web of Science ®Google Scholar
• SDBaker, RHvan Schaik, LPRivory, et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 2004;10:8341-50
   PubMed Web of Science ®Google Scholar
• SMLichtman, AHurria, CTCirrincione, et al. Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol 2012;23:632-8
   PubMed Web of Science ®Google Scholar
• AHurria, SMLichtman. Clinical pharmacology of cancer therapies in older adults. Br J Cancer 2008;98:517-22
   PubMed Web of Science ®Google Scholar
• DLHershman, TShao. Anthracycline cardiotoxicity after breast cancer treatment. Oncology (Williston Park) 2009;23:227-34
   PubMed Web of Science ®Google Scholar
• DDVon Hoff, MRozencweig, MPiccart. The cardiotoxicity of anticancer agents. Semin Oncol 1982;9:23-33
   PubMed Web of Science ®Google Scholar
• RJMaggiore, CPGross, KTogawa, et al. Use of complementary medications among older adults with cancer. Cancer 2012;118:4815-23
   PubMed Web of Science ®Google Scholar
• SEngdal, OKlepp, OGNilsen. Identification and exploration of herb-drug combinations used by cancer patients. Integr Cancer Ther 2009;8:29-36
   PubMed Web of Science ®Google Scholar
• ASparreboom, MCCox, MRAcharya, WDFigg. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004;22:2489-503
   PubMed Web of Science ®Google Scholar
• MEHamaker, CSeynaeve, ANWymenga, et al. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists’ group. Breast 2014;23:81-7
   PubMed Web of Science ®Google Scholar
• NWidmer, CBardin, EChatelut, et al. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies. Eur J Cancer 2014;50:2020-36
   PubMed Web of Science ®Google Scholar
• KDoki, MHomma, KKuga, et al. Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism. Br J Clin Pharmacol 2009;68:89-96
   PubMed Web of Science ®Google Scholar
• JEDesmarais, KJLooper. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 2009;70:1688-97
   PubMed Web of Science ®Google Scholar
• NLHenry, VStearns, DAFlockhart, et al. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry 2008;165:1251-5
   Web of Science ®Google Scholar
• AUBuzdar, JFRobertson, WEiermann, JMNabholtz. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 2002;95:2006-16
   PubMed Web of Science ®Google Scholar
• NGarcia-Giralt, MRodriguez-Sanz, DPrieto-Alhambra, et al. Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study. Breast Cancer Res Treat 2013;140:385-95
   PubMed Web of Science ®Google Scholar
• JRobert, LGianni. Pharmacokinetics and metabolism of anthracyclines. Cancer Surv 1993;17:219-52
   PubMedGoogle Scholar
• SMSwain, FSWhaley, MSEwer. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869-79
   PubMed Web of Science ®Google Scholar
• JLi, PRGwilt. The effect of age on the early disposition of doxorubicin. Cancer Chemother Pharmacol 2003;51:395-402
   PubMed Web of Science ®Google Scholar
• JRWade, AWKelman, DJKerr, et al. Variability in the pharmacokinetics of epirubicin: a population analysis. Cancer Chemother Pharmacol 1992;29:391-5
   PubMed Web of Science ®Google Scholar
• MSandstrom, HLindman, PNygren, et al. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol 2006;58:143-56
   PubMed Web of Science ®Google Scholar
• PFargeot, JBonneterre, HRoche, et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J Clin Oncol 2004;22:4622-30
   PubMed Web of Science ®Google Scholar
• DCrivellari, KPGray, SDellapasqua, et al. Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a “standard chemotherapy regimen”: the CASA randomized trial. Breast 2013;22:130-7
   PubMed Web of Science ®Google Scholar
• UBasso, ARoma, ABrunello, et al. Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥ 70 years). J Geriatr Oncol 2013;4:340-5
   PubMed Web of Science ®Google Scholar
• CFalandry, EBrain, MBonnefoy, et al. Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trial. Eur J Cancer 2013;49:2806-14
   PubMed Web of Science ®Google Scholar
• ASparreboom, JVerweij. Paclitaxel pharmacokinetics, threshold models, and dosing strategies. J Clin Oncol 2003;21:2803-4; author reply 05-6
   PubMed Web of Science ®Google Scholar
• SMLichtman, AHurria, CTCirrincione, et al. Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol 2011
   PubMedGoogle Scholar
• CHSmorenburg, AJten Tije, JVerweij, et al. Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer 2003;39:196-202
   PubMed Web of Science ®Google Scholar
• AHurria, MSBlanchard, TWSynold, et al. Age-related changes in nanoparticle albumin-bound Paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional age. Oncologist 2015;20:37-44
   PubMed Web of Science ®Google Scholar
• MAapro, STjulandin, PBhar, WGradishar. Weekly nab-paclitaxel is safe and effective in >/=65 years old patients with metastatic breast cancer: a post-hoc analysis. Breast 2011;20:468-74
   PubMed Web of Science ®Google Scholar
• XPivot, ASchneeweiss, SVerma, et al. Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. Eur J Cancer 2011;47:2387-95
   PubMed Web of Science ®Google Scholar
• AHurria, MTFleming, SDBaker, et al. Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res 2006;12:6100-5
   PubMed Web of Science ®Google Scholar
• DCrivellari, MBonetti, MCastiglione-Gertsch, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 2000;18:1412-22
   PubMed Web of Science ®Google Scholar
• FPerrone, FNuzzo, FDi Rella, et al. Weekly docetaxel vs CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomised phase 3 ELDA trial. Ann Oncol 2015;26(4):675-82
   PubMed Web of Science ®Google Scholar
• JCassidy, CTwelves, DCameron, et al. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol 1999;44:453-60
   PubMed Web of Science ®Google Scholar
• ZDaher Abdi, SLavau-Denes, APremaud, et al. Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer. Cancer Chemother Pharmacol 2014;73:1285-93
   PubMed Web of Science ®Google Scholar
• JCassidy, CTwelves, EVan Cutsem, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13:566-75
   PubMed Web of Science ®Google Scholar
• JFeliu, PEscudero, FLlosa, et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol 2005;23:3104-11
   PubMed Web of Science ®Google Scholar
• WHu, JShi, YSheng, et al. Clinical study of adjuvant capecitabine monotherapy in Chinese elderly patients (aged 55-70) with stage IIa breast cancer. Onkologie 2010;33:433-6
   PubMed Web of Science ®Google Scholar
• HWildiers, MSHighley, EAde Bruijn, ATvan Oosterom. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 2003;42:1213-42
   PubMed Web of Science ®Google Scholar
• BNStein, NJPetrelli, HODouglass, et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995;75:11-17
   PubMed Web of Science ®Google Scholar
• DJSargent, RMGoldberg, SDJacobson, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345:1091-7
   PubMed Web of Science ®Google Scholar
• RMGoldberg, ITabah-Fisch, HBleiberg, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006;24:4085-91
   PubMed Web of Science ®Google Scholar
• GFolprecht, DCunningham, PRoss, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004;15:1330-8
   PubMed Web of Science ®Google Scholar
• RSorio, IRobieux, EGalligioni, et al. Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer 1997;33:301-3
   PubMed Web of Science ®Google Scholar
• AGauvin, FPinguet, SCuline, et al. Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. Clin Cancer Res 2000;6:2690-5
   PubMed Web of Science ®Google Scholar
• MWong, RLBalleine, EYBlair, et al. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol 2006;24:2448-55
   PubMed Web of Science ®Google Scholar
• MBaweja, VJSuman, TRFitch, et al. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients > or = 65 years of age: an NCCTG study. Ann Oncol 2006;17:623-9
   PubMed Web of Science ®Google Scholar
• ARossi, CGridelli, VGebbia, et al. Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer. Anticancer Res 2003;23:1657-64
   PubMed Web of Science ®Google Scholar
• CMKelly, DGPower, SMLichtman. Targeted therapy in older patients with solid tumors. J Clin Oncol 2014;32:2635-46
   PubMed Web of Science ®Google Scholar
• DJSlamon, BLeyland-Jones, SShak, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• DCardinale, AColombo, RTorrisi, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010;28:3910-16
   PubMed Web of Science ®Google Scholar
• MChavez-MacGregor, NZhang, TABuchholz, et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 2013;31:4222-8
   PubMed Web of Science ®Google Scholar
• AThomas-Schoemann, BBlanchet, CBardin, et al. Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol 2014;89:179-96
   PubMed Web of Science ®Google Scholar
• KIPritchard, HABurrisIII, YIto, et al. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer 2013;13:421-32; e8
   PubMed Web of Science ®Google Scholar
• JBaselga, JCortes, SBKim, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-19
   PubMed Web of Science ®Google Scholar
• SVerma, DMiles, LGianni, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91
   PubMed Web of Science ®Google Scholar
• CEGeyer, JForster, DLindquist, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43
   PubMed Web of Science ®Google Scholar
• JPCrown, HABurrisIII, FBoyle, et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2008;112:317-25
   PubMed Web of Science ®Google Scholar